Bosentan

Generic Name
Bosentan
Brand Names
Stayveer, Tracleer
Drug Type
Small Molecule
Chemical Formula
C27H29N5O6S
CAS Number
147536-97-8
Unique Ingredient Identifier
XUL93R30K2
Background

Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Indication

Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).

Associated Conditions
NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections
Associated Therapies
-
Clinical Trials
Related News

FUTURE 3 Study Extension

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Bosentan
First Posted Date
2011-04-19
Last Posted Date
2021-06-16
Lead Sponsor
Actelion
Target Recruit Count
58
Registration Number
NCT01338415
Locations
🇮🇳

CARE Hospitals, Cardiology Dep. Hyderabad - Site 5302, Hyderabad, India

🇷🇸

Institut za zdravstvenu zaštitu majke i deteta Srbije "Dr Vukan Čupić", Služba za ispitivanje i lečenje bolesti srca i krvnih sudova - Site 3902, Belgrade, Serbia

🇧🇾

The Republican Scientific-Practical Center "Cardiology" - Site 3001, Minsk, Belarus

and more 33 locations

Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.

First Posted Date
2011-02-09
Last Posted Date
2013-04-19
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
75
Registration Number
NCT01292551
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇸🇪

Karolinska Institutet, Stockholm, Sweden

🇩🇰

Rigshospitalet, Copenhagen, Denmark

and more 1 locations

Bosentan for Severe Mitral Valve Dysfunction

First Posted Date
2011-01-05
Last Posted Date
2011-01-28
Lead Sponsor
General Hospital of Chalkida
Target Recruit Count
10
Registration Number
NCT01270750
Locations
🇬🇷

General Hospital of Chalkida, Chalkida, Evoia, Greece

Effect of Bosentan in Scleroderma Renal Crisis

Phase 2
Completed
Conditions
Scleroderma Renal Crisis
Interventions
Drug: Bosentan
First Posted Date
2010-11-16
Last Posted Date
2016-07-06
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
16
Registration Number
NCT01241383
Locations
🇫🇷

Pôle de médecine interne Centre de référence Maladies rares Groupe I Maladies systémiques et maladies auto-immunes rares en particulier Vascularites nécrosantes et les sclérodermies - Hôpital Cochin, Paris, France

Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: bosentan
First Posted Date
2010-10-19
Last Posted Date
2017-12-11
Lead Sponsor
Actelion
Target Recruit Count
64
Registration Number
NCT01223352
Locations
🇨🇳

Shanghai Children's Medical Center - Site 5102, Shanghai, China

🇫🇷

Hopital Necker-Enfants Malades, Service de Cardiologie Pédiatrique - Site 2201, Paris, France

🇩🇪

Justus-Liebig-Universität Giessen, Kinderherzzentrum - Site 1403, Giessen, Germany

and more 45 locations

Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.

Phase 3
Completed
Conditions
Heart Septal Defects, Atrial
Interventions
Drug: Placebo
Drug: Bosentan
First Posted Date
2010-10-11
Last Posted Date
2014-03-05
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
10
Registration Number
NCT01218607
Locations
🇧🇪

University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium

Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery

Not Applicable
Conditions
Congenital Heart Disease
Interventions
Drug: Bosentan
First Posted Date
2010-08-19
Last Posted Date
2015-12-22
Lead Sponsor
Berto J Bouma
Target Recruit Count
100
Registration Number
NCT01184404
Locations
🇳🇱

Academic Medical Center, Amsterdam, NH, Netherlands

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

First Posted Date
2010-04-09
Last Posted Date
2015-07-21
Lead Sponsor
University of Edinburgh
Target Recruit Count
10
Registration Number
NCT01100736
Locations
🇬🇧

Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Phase 2
Completed
Conditions
Melanoma
Interventions
Drug: Placebo
Drug: Bosentan
First Posted Date
2009-11-06
Last Posted Date
2015-04-30
Lead Sponsor
Actelion
Target Recruit Count
80
Registration Number
NCT01009177
Locations
🇦🇺

Barwon Health - The Geelong Hospital, Geelong, Australia

🇦🇺

Sydney Haematology and Oncology Unit, Hornsby, Australia

🇦🇺

Cabrini Hopsital - Oncology Department, Malvern, Australia

and more 9 locations

Endothelin Blockade in Patients With Single Ventricle Physiology

Not Applicable
Completed
Conditions
Congenital Heart Disease
Interventions
Drug: Bosentan
First Posted Date
2009-10-06
Last Posted Date
2015-02-27
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
10
Registration Number
NCT00989911
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy